• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Rituximab for chronic lymphocytic leukemia.
【24h】

Rituximab for chronic lymphocytic leukemia.

机译：利妥昔单抗用于慢性淋巴细胞性白血病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Rituximab is a high-affinity chimeric mouse anti-CD20 monoclonal antibody, currently used for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and autoimmune disorders. AREAS COVERED: This article summarizes recent achievements in the clinical activity and toxicity of rituximab in the treatment of patients with CLL. A literature search was conducted of the PubMed MEDLINE database for articles in English. Publications from 2000 through January 2012 were scrutinized. The search terms used were rituximab in conjunction with chronic lymphocytic leukemia or CLL. Conference proceedings from the previous 5 years of The American Society of Hematology, The European Hematology Association, and American Society of Clinical Oncology were searched manually. Additional relevant publications were obtained by reviewing the references from the chosen articles. EXPERT OPINION: Rituximab is an active drug in CLL when used as a single agent and in combination with chemotherapy, particulary with fludarabine or fludarabine and cyclophosphamide (R-FC regimen). In addition, rituximab may be an optimal therapeutic choice of treatment for CLL-associated autoimmune cytopenias.
机译：简介：利妥昔单抗是一种高亲和力的嵌合小鼠抗CD20单克隆抗体，目前用于治疗非霍奇金淋巴瘤（NHL），慢性淋巴细胞性白血病（CLL）和自身免疫性疾病。涵盖的领域：本文总结了利妥昔单抗治疗CLL患者的临床活性和毒性方面的最新成就。对PubMed MEDLINE数据库进行了英文文献检索。对从2000年到2012年1月的出版物进行了审查。所用的检索词是利妥昔单抗联合慢性淋巴细胞性白血病或CLL。手动搜索了美国血液学会，欧洲血液学协会和美国临床肿瘤学会过去5年的会议记录。通过查阅所选文章的参考文献，可以获得其他相关出版物。专家意见：利妥昔单抗作为单一药物并与化学疗法（特别是与氟达拉滨或氟达拉滨和环磷酰胺）联合使用时，是一种CLL中的活性药物（R-FC方案）。另外，利妥昔单抗可能是CLL相关自身免疫性血细胞减少症的最佳治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号